Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-ABC: Targeted Antibiotics for P. aeruginosa in Chronic Pulmonary Disease
NCT03262142Phase 4Terminated
- Sponsor
- COPD360Net
- Start
- Jan 2018
- Primary completion
- Mar 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of piperacillin + tazobactam, ciprofloxacin in chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, Pseudomonas aeruginosa infection, sponsored by COPD360Net. Started Jan 2018; status: terminated.
02
Drugs
piperacillin + tazobactamciprofloxacin
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchiectasisasthmaPseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT03262142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262142.